Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Breast Cancer
Sponsor: Abramson Cancer Center at Penn Medicine
Summary
Up to 30 evaluable participants with known or suspected breast cancer (BIRADS 5 by imaging) will undergo FTT PET/CT imaging before primary surgery or neoadjuvant therapy. Patients undergoing neoadjuvant therapy may choose to have a second FTT PET/CT scan after the start of therapy (1 days to 3 weeks). FTT PET/CT uptake will be correlated with pathology measures and treatment response, in subjects undergoing neoadjuvant therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2017-02-22
Completion Date
2026-02-22
Last Updated
2025-09-10
Healthy Volunteers
No
Conditions
Interventions
[18F]FluorThanatrace
\[18F\]FluorThanatrace is a radiotracer for PET/CT
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, United States